City Therapeutics Raises $200 Million in Upsized IPO Amid Biotech Market Activity

Published
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 RobotToday Industry Briefing RobotToday Industry Briefing graphic: a blueprint-style humanoid robot outline with annotations for perception, actuation and mobility, next to the Industry Briefing wordmark. PERCEPTION ACTUATION MOBILITY ROBOTTODAY Industry Briefing Editor-curated robotics news from around the world HUMANOIDS/ INDUSTRIAL / DRONES / AI & RESEARCH RobotToday robottoday.com/industry-briefing
RobotToday Industry Briefing

This week, three IPOs and two SPACs were priced, with City Therapeutics leading the charge by pricing its upsized IPO at the midpoint, raising $200 million and achieving a market cap of $1.0 billion.

The successful pricing of City Therapeutics is significant as it reflects investor confidence in the biotech sector, particularly for companies in early-stage clinical trials. This move may encourage other biotech firms to pursue public offerings, potentially revitalizing the market.

Looking ahead, the continued interest in biotech IPOs and SPACs will be crucial to monitor, especially as more companies consider going public. No further timeline was disclosed at the time of publication.

Original report

U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings

Seekingalpha.com
Read at Seekingalpha.com

More related news

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

Related Suppliers

Brew City Robotics LLC

Milwaukee-area system integrator delivering turn-key robotic cells, custom machines, and industrial controls for small and mid-size manufacturers.

DeepGlint 格灵深瞳

Beijing-listed AI vision company (SSE:688207) specializing in behavioral vision, edge computing platforms, and multimodal AI for smart cities.

LG PRI LG生产技术研究院

LG Electronics' Production Engineering Research Institute offering AI-powered smart factory solutions; targets multi-trillion KRW external revenue by 2030.

Industrial Manufacturing Logistics & Supply Chain Robot Manufacturer

Ganymed Robotics

Ganymed Robotics is a Paris-based medtech startup developing a marker-less, co-manipulated robotic assistant for total knee arthroplasty.

Starpath Robotics

Hawthorne, CA startup building Shadow Voyager autonomous lunar ice-mining rovers for the Starmine propellant system, plus low-cost Starlight space solar panels.

AIRO Group Holdings

McLean, Virginia aerospace holding company listed on Nasdaq as AIRO since its June 2025 IPO; spans drones, avionics, training, and air mobility.

Osaro

Osaro is a USA AI-powered warehouse robotics company founded in 2015 that delivers software-defined automation for piece picking, bagging, kitting, and.

Logistics & Supply Chain Robot Manufacturer Mobile Manipulator

Orthopus

Nantes maker of the Supporter, a CE Class I powered arm support offsetting up to 4 kg on a wheelchair or table, designed open-source with its users.

Let's Go Robotics

US-based life sciences laboratory automation specialist offering precision dispensing and liquid handling systems.

Healthcare & Senior Care Robot Manufacturer Software & Algorithm Provider

Interstellar Lab

French biotech company developing AI-controlled closed-loop farming pods for Earth and space, including BioPod autonomous greenhouses and life support systems.

Agriculture
RobotToday Initiative

Robotics needs a service framework.

RSF defines a common language for robot service capability, lifecycle operations, certification pathways, and service-provider networks.

inJoin the RobotToday community on LinkedIn

Daily robotics news, in-depth analysis, conference highlights, and discussions with professionals worldwide.